Last reviewed · How we verify
thymalfasin (thymosin alpha 1)
Thymalfasin (thymosin alpha 1) is a peptide that stimulates the immune system by activating T cells and natural killer cells.
Thymalfasin (thymosin alpha 1) is a peptide that stimulates the immune system by activating T cells and natural killer cells. Used for Severe herpes simplex virus infections, Severe fungal infections.
At a glance
| Generic name | thymalfasin (thymosin alpha 1) |
|---|---|
| Sponsor | SciClone Pharmaceuticals |
| Drug class | Immunomodulator |
| Target | T cell receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Thymalfasin works by binding to specific receptors on the surface of immune cells, triggering a cascade of signals that enhance their activity and proliferation. This leads to an increase in the production of cytokines, which are signaling molecules that help to coordinate the immune response. By boosting the activity of T cells and natural killer cells, thymalfasin can help to fight off infections and diseases.
Approved indications
- Severe herpes simplex virus infections
- Severe fungal infections
Common side effects
- Injection site reaction
- Fever
- Headache
Key clinical trials
- Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma (PHASE2)
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
- The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies (PHASE1)
- A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer (PHASE2)
- Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) (NA)
- The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC (PHASE2)
- Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thymalfasin (thymosin alpha 1) CI brief — competitive landscape report
- thymalfasin (thymosin alpha 1) updates RSS · CI watch RSS
- SciClone Pharmaceuticals portfolio CI